MAPT and Alzheimer disease: One influential conceptualization is that biomarkers of AD can be divided into those that are sensitive to cerebral Aβ-plaque deposition (e.g. amyloid imaging, CSF Aβ) and those that are sensitive to neuronal dysfunction and injury (e.g. FDG PET, structural MRI, CSF total tau/phosphorylated tau) (Albert et al., 2011; Jack et al., 2010, 2013a).